Dissecting cellulitis of the scalp (DCS) is a rare condition characterized by painful inflammatory nodules and abscesses on the scalp, often leading to sinus tracts and scarring alopecia. We present a case of DCS in a 26-year-old male who experienced significant clinical improvement following a short course of upadacitinib, a Janus kinase (JAK) inhibitor. The patient received multiple standard treatments such as topical antimicrobials, oral antibiotics, corticosteroids, and intralesional triamcinolone injections, with limited success. However, following the initiation of upadacitinib, the patient reported reduced pain, pustular draining, and bleeding, with significantly improved quality of life. To our knowledge, there is currently a paucity of literature documenting the use of JAK inhibitors for DCS. This case aims to highlight the potential of JAK inhibitors as a therapy for refractory DCS, a condition with limited treatment options.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10868624 | PMC |
| http://dx.doi.org/10.7759/cureus.52377 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dissecting Cellulitis of the Scalp.
Kans J Med
November 2024
Department of Dermatology, The University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
Dissecting Cellulitis Presenting After Hair Restoration Surgery.
Cureus
November 2024
Dermatology, Hospital Universitario "Dr. José Eleuterio González", Nuevo León, MEX.
Dissecting cellulitis (DC) of the scalp is a chronic inflammatory condition marked by neutrophilic cicatricial alopecia, often linked to staphylococcal antigens. This case report details a 34-year-old male with scarring acne who developed DC following follicular unit extraction (FUE) approximately four months prior. Trichoscopic examination revealed brown pigmented dots, erythema, and melicerous crusts.
View Article and Find Full Text PDFPreventing Breast Cancer-Related Lymphedema: A Comprehensive Analysis of a 9-Year Single-Center Experience of Prophylactic Lymphovenous Bypass.
Ann Surg Oncol
December 2024
Department of Plastic and Reconstructive Surgery, The Ohio State University, Columbus, OH, USA.
Background: Prophylactic lymphovenous bypass (pLVB) is a microsurgical technique aimed to prevent breast cancer-related lymphedema (BCRL) after axillary lymph node dissection (ALND) by redirecting lymphatic flow from the ligated lymphatics into neighboring veins. This report describes the authors' 9-year institutional experience of pLVB in patients undergoing ALND to prevent BCRL.
Methods: Patients who underwent ALND were reviewed.
Dissecting cellulitis mimicking kerion in a 9-year-old boy.
JAAD Case Rep
December 2024
Department of Dermatology, University of Connecticut School of Medicine, Farmington, Connecticut.
Off-label dermatologic uses of IL-23 inhibitors.
J Dermatolog Treat
December 2024
Department of Dermatology, University of Illinois College of Medicine, Chicago, IL, USA.
Background: While IL-23 inhibitors, which include guselkumab, tildrakizumab, and risankizumab, are currently FDA-approved solely for the treatment of psoriasis, several other inflammatory skin conditions have been associated with elevated IL-23 levels. The purpose of this review is to summarize and interpret the literature surrounding the off-label uses of IL-23 inhibitors in dermatologic practice.
Methods: We conducted searches on PubMed and for clinical trials, observational studies, case series, and case reports assessing use of the three IL-23 inhibitors for non-psoriatic dermatologic conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!